SRStephen Rhodes

Stephen Rhodes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephen Rhodes has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Erectile Dysfunction as a Predictor of Subclinical Atherosclerosis: A Community Health Assessment Using Coronary Calcium Scoring in Underserved Cleveland, Ohio

    by Hachem Ziadeh, Jad Badreddine, Thriaksh Rajan, Yann Chemali, Stephen Rhodes, Lydia Beard, Ramy Abou Ghayda


  • Open Access

    Chemotherapy and the somatic mutation burden of sperm

    by Shany Picciotto, Camilo Arenas-Gallo, Amos Toren, Ruty Mehrian-Shai, Bryan Daly, Stephen Rhodes, Megan Prunty, Ruolin Liu, Anyull Bohorquez, Marta Grońska-PęSki, et al.

    Many chemotherapeutic agents impair cancer growth by inducing DNA damage. The impact of these agents on mutagenesis in normal cells, including sperm, is largely unknown. Here, we applied high-fidelity duplex sequencing to 94 samples from 36 individuals exposed to diverse chemotherapies and 32 controls. We found that in many of the sperm samples from men exposed to chemotherapy, the mutation burden was elevated as compared with controls and the expected burden based on trio studies, with 1 patient having a more than 10-fold increase over that expected for age. Saliva from this same individual also had a markedly higher mutation burden. We then validated this finding using other tissues, also finding an increased mutation burden in the blood and liver of many patients exposed to chemotherapy as compared with unexposed controls. Similarly, mice treated with 3 cycles of cisplatin had an increased mutation burden in sperm but also in the liver and hematopoietic progenitor cells. These results suggest an association between cancer therapies and mutation burden, with implications for counseling patients with cancer considering banking sperm before therapy and for cancer survivors considering the trade-offs of using banked sperm as compared with conceiving naturally.


  • Reply by Authors

    by Camilo Arenas-Gallo, Patrick Lewicki, Megan Prunty, Aaron Brant, Stephen Rhodes, Spyridon P. Basourakos, Alec Zhu, Bashir Al Hussein Al Awamlh, Jonathan E. Shoag

  • Open Access

    The outcomes of same-day discharge following holmium laser enucleation of the prostate (HoLEP) surgeries: our experience during the COVID-19 pandemic

    by Jad Badreddine, Helen Sun, Kimberly Tay, Stephen Rhodes, Daniel Chen, Michael Zell, Irina Jaeger, Amihay Nevo

    Objective To describe the outcomes of Same-Day Discharge (SDD) following Holmium Laser Enucleation of the Prostate (HoLEP) in patients during the COVID-19 pandemic. Methods A retrospective review of HoLEP surgeries at a single institution between January 2021 and March 2022 was performed. Patient demographic and operative data were collected, and postoperative outcomes were evaluated in terms of safety and efficacy and compared in both groups using a t-test and chi-square test. Logistic regression was also performed to identify factors that correlate with the failure of SDD. Results A total of 155 patients were identified; 135 patients were successfully discharged on the same day and 20 were admitted (87% SDD rate). Admitted HoLEP patients had a significantly higher median prostate-specific antigen (5.7 vs 3.9 ng/dL, P < 0.001), prostate volume (152.3 vs 100.6 mL, P < 0.001), and enucleated tissue weight (90.3 vs 56.9 g, P = 0.04) compared to the SDD group. The SDD group had a 2.9% (n = 4) readmission rate and a 5.2% (n = 7) Emergency Department (ED) visit rate. There was no significant difference in the rate of postoperative ED visits (P = 0.64), readmissions (P = 0.98), complications, and catheterization time (P = 0.98) between both groups. Preoperative predictors of SDD failure included prostate gland volume > 150 mL (OR = 7.17; CI 2.01–25.67; P < 0.01) and history of antiplatelet/anticoagulation use (OR = 6.59; CI 2.00–21.67; P < 0.01). Conclusion Same-day discharge following HoLEP is a safe and effective approach that can be performed in most patients using a liberal discharge criteria and relying on postoperative findings only.